Stay updated on Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial
Sign up to get notified when there's something new on the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page.

Latest updates to the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe history now includes Revision: v3.3.3, and the HHS Vulnerability Disclosure and Revision: v3.3.2 entries were removed.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe record history now includes core results-related sections such as Results Posted, Outcome Measures (Results), Adverse Events, Baseline Characteristics, and Participant Flow, along with More Information and Limitations and Caveats; the previous entry 'Results Submitted' appears to be removed.SummaryDifference1%

- Check41 days agoChange DetectedA new revision entry v3.3.2 was added to the Record History, replacing the previous v3.2.0. No substantive changes to the study information are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedRemoved the general government funding/operating status notice from the page. The notice previously informed users about potential downtime and where to check for updates (opm.gov).SummaryDifference0.7%

- Check62 days agoChange DetectedNew version entry dated 2025-02-12 shows updated Recruitment Status and ongoing Study Status details in the record history. The change reflects current trial activity and availability information as recorded on ClinicalTrials.gov.SummaryDifference0.2%

- Check70 days agoChange DetectedThe record history shows two new Results Submission Events and one removed, reflecting updates to how results submissions are tracked. This is an administrative log update and does not modify the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezolizumab+Bevacizumab 1st Line in NSCLC (TELMA) Clinical Trial page.